| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $125,000 | 1 | 5 |
Sells | $641,375 | 21 | 95 |
| MCLAUGHLIN KEVIN F | director | 1 | $125,000 | 0 | $0 | $125,000 |
| Allen Robert D. III | Chief Scientific Officer | 0 | $0 | 2 | $27,573 | $-27,573 |
| Duke William E. | Chief Financial Officer | 0 | $0 | 2 | $29,808 | $-29,808 |
| Green Julie | Chief Human Resources Officer | 0 | $0 | 2 | $29,808 | $-29,808 |
| Lee Timothy Edward | Chief Commercial Officer | 0 | $0 | 2 | $29,808 | $-29,808 |
| Andersen Jill | Chief Legal Officer, Secretary | 0 | $0 | 2 | $49,677 | $-49,677 |
| MCGUIRE TERRANCE | director | 0 | $0 | 11 | $474,701 | $-474,701 |
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Over the last 12 months, insiders at Invivyd, Inc. have bought $125,000 and sold $641,375 worth of Invivyd, Inc. stock.
On average, over the past 5 years, insiders at Invivyd, Inc. have bought $125,000 and sold $10.47M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MCLAUGHLIN KEVIN F (director) — $125,000.
The last purchase of 50,000 shares for transaction amount of $125,000 was made by MCLAUGHLIN KEVIN F (director) on 2025‑11‑19.
| 2025-11-19 | MCLAUGHLIN KEVIN F | director | 50,000 0.0377% | $2.50 | $125,000 | -8.92% | ||
| 2025-08-19 | Sale | Andersen Jill | Chief Legal Officer, Secretary | 49,402 0.0409% | $0.57 | $27,991 | +187.22% | |
| 2025-08-19 | Sale | Lee Timothy Edward | Chief Commercial Officer | 29,643 0.0245% | $0.57 | $16,796 | +187.22% | |
| 2025-08-19 | Sale | Allen Robert D. III | Chief Scientific Officer | 27,420 0.0227% | $0.57 | $15,536 | +187.22% | |
| 2025-08-19 | Sale | Green Julie | Chief Human Resources Officer | 29,643 0.0245% | $0.57 | $16,796 | +187.22% | |
| 2025-08-19 | Sale | Duke William E. | Chief Financial Officer | 29,643 0.0245% | $0.57 | $16,796 | +187.22% | |
| 2025-08-18 | Sale | Andersen Jill | Chief Legal Officer, Secretary | 33,352 0.0311% | $0.65 | $21,685 | +181.36% | |
| 2025-08-18 | Sale | Lee Timothy Edward | Chief Commercial Officer | 20,013 0.0187% | $0.65 | $13,012 | +181.36% | |
| 2025-08-18 | Sale | Allen Robert D. III | Chief Scientific Officer | 18,512 0.0173% | $0.65 | $12,037 | +181.36% | |
| 2025-08-18 | Sale | Green Julie | Chief Human Resources Officer | 20,013 0.0187% | $0.65 | $13,012 | +181.36% | |
| 2025-08-18 | Sale | Duke William E. | Chief Financial Officer | 20,013 0.0187% | $0.65 | $13,012 | +181.36% | |
| 2024-12-31 | Sale | MCGUIRE TERRANCE | director | 103,474 0.0894% | $0.45 | $46,098 | +89.61% | |
| 2024-12-30 | Sale | MCGUIRE TERRANCE | director | 86,545 0.0685% | $0.48 | $41,784 | +81.50% | |
| 2024-12-27 | Sale | MCGUIRE TERRANCE | director | 83,744 0.0705% | $0.52 | $43,647 | +64.23% | |
| 2024-12-26 | Sale | MCGUIRE TERRANCE | director | 83,817 0.0712% | $0.54 | $45,563 | +57.86% | |
| 2024-12-24 | Sale | MCGUIRE TERRANCE | director | 68,161 0.0566% | $0.51 | $34,503 | +64.07% | |
| 2024-12-23 | Sale | MCGUIRE TERRANCE | director | 75,776 0.0605% | $0.45 | $34,076 | +77.44% | |
| 2024-12-20 | Sale | MCGUIRE TERRANCE | director | 119,805 0.1005% | $0.42 | $50,725 | +85.63% | |
| 2024-12-19 | Sale | MCGUIRE TERRANCE | director | 152,067 0.1277% | $0.43 | $65,951 | +88.99% | |
| 2024-12-18 | Sale | MCGUIRE TERRANCE | director | 74,764 0.066% | $0.47 | $35,087 | +82.42% |
| Increased Positions | 45 | +55.56% | 102M | +168.92% |
| Decreased Positions | 33 | -40.74% | 14M | -23.14% |
| New Positions | 24 | New | 86M | New |
| Sold Out Positions | 16 | Sold Out | 11M | Sold Out |
| Total Postitions | 93 | +14.81% | 149M | +145.78% |
| Janus Henderson Group Plc | $58,889.00 | 9.16% | 25.38M | +25M | New | 2025-09-30 |
| Point72 Asset Management, L.P. | $47,101.00 | 7.33% | 20.3M | +20M | New | 2025-09-30 |
| Maverick Capital Ltd | $44,013.00 | 6.85% | 18.97M | +9M | +85.46% | 2025-09-30 |
| Ra Capital Management, L.P. | $39,716.00 | 6.18% | 17.12M | +17M | New | 2025-09-30 |
| Mithril Ii Gp Lp | $26,080.00 | 4.06% | 11.24M | 0 | 0% | 2025-09-30 |
| Driehaus Capital Management Llc | $23,444.00 | 3.65% | 10.11M | +10M | New | 2025-09-30 |
| M28 Capital Management Lp | $21,456.00 | 3.34% | 9.25M | 0 | 0% | 2025-09-30 |
| Adar1 Capital Management, Llc | $17,101.00 | 2.66% | 7.37M | +7M | New | 2025-09-30 |
| 683 Capital Management, Llc | $14,616.00 | 2.27% | 6.3M | +3M | +105.21% | 2025-09-30 |
| Vanguard Group Inc | $13,370.00 | 2.08% | 5.76M | +2M | +46.72% | 2025-09-30 |